[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"imaging-examination-shows-at-least-one-site-with-bone-metastases-from-soild-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:imaging-examination-shows-at-least-one-site-with-bone-metastases-from-soild-tumors":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100533073","phase-3-a-study-to-assess-the-prevention-of-bone-related-events-in-patients-with-bone-metastases-from-malignant-solid-tumors-treated-with-jmt103-compared-to-zoledronic-acid-100533073",false,"NCT06221072","A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid","A Phase III, Multicenter, Randomized, Double-blind Clinical Trail to Assess JMT103 Compared to Azoledronic Acid for the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors","Inclusion Criteria:\n\n1. Age: older than 18 years;\n2. Breast cancer, prostate cancer, lung cancer and other solid tumors diagnosed by histological or cytological examination (prostate patients should also meet: castration-resistant prostate cancer with serum testosterone \\\u003C50 ng\u002FdL or 1.7 nmol\u002FL and serum PSA progression after surgery or drug castration treatment);\n3. Patients with imaging studies showing at least one tumor bone metastasis;\n4. With a good organ function;\n5. Expected survival of at least 6 months.\n\nExclusion Criteria:\n\n1. Previous or ongoing osteomyelitis or osteonecrosis of the jaw; dental or oral surgery; acute dental or jaw disease requiring oral surgery; invasive dental procedures planned during the study; patients with pulpitis during the screening period;\n2. Radiotherapy or surgery for the bone metastases is planned during the study;\n3. Patients with brain metastasis or meningeal metastasis (patients with neurological symptoms should undergo MRI\u002FCT examination to exclude patients with brain metastasis);\n4. Patients with bone metabolic diseases \\[e.g., Paget's disease, Cushing's syndrome, hyperprolactinemia, hyperthyroidism\u002Fhypothyroid (except for hypothyroidism with normal TSH, FT3, and FT4 after stable thyroid hormone replacement therapy, and subclinical hypothyroidism that does not need to be treated), hyper\u002Fhypoparathyroidism, etc.\\];\n5. Uncontrolled concurrent diseases, including but not limited to: uncontrolled diabetes mellitus (≥grade 3, NCI-CTCAE 5.0), symptomatic congestive heart failure, hypertension (BP\\> 150\u002F90 mmHg after standard therapy), unstable angina, arrhythmia requiring medical or instrumental treatment, history of myocardial infarction within 6 months, echocardiography with left ventricular ejection fraction \\\u003C50%;\n6. Treatment with anti-RANKL antibody, bisphosphonates (except for bone scan purposes) within 6 months prior to the first dose;\n7. Patients considered by the investigator as unsuitable for this study (such as poor compliance, etc.).","ALL","18 Years",{"count":19,"type":20},1360,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a phase Ⅲ, multicenter, randomized, double-blind, study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from malignant solid tumors. The purpose of this study is to determine if JMT103 is non-inferior to zoledronic acid.",[26],"Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors","NOT_YET_RECRUITING","2024-01-14",{"date":30,"type":31},"2024-01-24","ACTUAL",{"date":33,"type":20},"2024-04-05",{"date":35,"type":20},"2028-05-31",{"name":37,"class":38},"Shanghai JMT-Bio Inc.","INDUSTRY"]